Cedarburg Hauser’s Denver, CO facility has been granted registration as a manufacturer of schedule II-V controlled substances by the U.S Drug Enforcement Agency (DEA). The new DEA registration status allows the company to manufacture controlled substances and provides additional capacity when added to its existing controlled substance manufacturing capabilities at its Grafton, WI facility.
"The GMP manufacturing and analytical method development expertise of Cedarburg Hauser's Denver facility may now be extended to DEA scheduled compounds," said vice president and general manager, Joe Guiles. "This further emphasizes these competencies, and represents an opportunity to expand our customer base and serve the needs of our existing customers."
"The development and manufacturing of controlled substances requires stringent controls and security measures," said Dan Childers, vice president of Quality Assurance and Regulatory Compliance. "DEA registration further illustrates the strength of the manufacturing, handling and storage controls in place at Cedarburg Hauser's Denver facility."